Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the Single-Use Pre-Filled Autoinjector for Exenatide
NCT02349802Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2013
- Primary completion
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by AstraZeneca. Primary endpoint: Number of device-related failure injections at 10 weeks. Started Feb 2013; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02349802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349802.